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Abstract
Introduction As large scale metabolic phenotyping is increasingly employed in preclinical studies and in the investigation of 
human health and disease the current LC–MS/MS profiling methodologies adopted for large sample sets can result in lengthy 
analysis times, putting strain on available resources. As a result of these pressures rapid methods of untargeted analysis may 
have value where large numbers of samples require screening.
Objectives To develop, characterise and evaluate a rapid UHP-HILIC-MS-based method for the analysis of polar metabolites 
in rat urine and then extend the capabilities of this approach by the addition of IMS to the system.
Methods A rapid untargeted HILIC LC–MS/MS profiling method for the analysis of small polar molecules has been devel-
oped. The 3.3 min separation used a Waters BEH amide (1 mm ID) analytical column on a Waters Synapt G2-Si Q-Tof 
enabled with ion mobility spectrometry (IMS). The methodology, was applied to the metabolic profiling of a series of rodent 
urine samples from vehicle-treated control rats and animals administered tienilic acid. The same separation was subsequently 
linked to IMS and MS to evaluate the benefits that IMS might provide for metabolome characterisation.
Results The rapid HILIC–MS method was successfully applied to rapid analysis of rat urine and found, based on the data 
generated from the data acquired for the pooled quality control samples analysed at regular intervals throughout the analysis, 
to be robust. Peak area and retention times for the compounds detected in these samples showed good reproducibility across 
the batch. When used to profile the urine samples obtained from vehicle-dosed control and those administered tienilic acid 
the HILIC-MS method detected 3007 mass/retention time features. Analysis of the same samples using HILIC–IMS–MS 
enabled the detection of 6711 features. Provisional metabolite identification for a number of compounds was performed 
using the high collision energy MS/MS information compared against the Metlin MS/MS database and, in addition, both 
calculated and measured CCS values from an experimentally derived CCS database.
Conclusion A rapid metabolic profiling method for the analysis of polar metabolites has been developed. The method has 
the advantages of speed and both reducing sample and solvent consumption compared to conventional profiling methods. 
The addition of IMS added an additional dimension for feature detection and the identification of metabolites.
Keywords Hydrophilic interaction chromatography · Metabolic phenotyping · IMS · LC–MS/MS
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1 Introduction
The application of untargeted metabolic phenotyping 
(metabolomics/metabonomics) to large scale preclinical 
metabolism/toxicological (Clarke and Haselden 2008; 
Lindon et al. 2005; Wurtz et al. 2017), and clinical or epi-
demiological (Dunn et al. 2015; Lewis et al. 2016) inves-
tigations has delivered new insights into the underlying 
biology of health, toxicity and disease. The key analytical 
tools employed in metabolic profiling are currently nuclear 
magnetic resonance (NMR) spectroscopy and mass spec-
trometry (MS), with the latter either via direct infusion 
(DIMS) or coupled to a chromatographic separation tech-
nique such as gas (GC–MS) or high performance liquid/
supercritical fluid chromatography (LC–MS/SFC–MS) or 
alternatively a separation based on capillary electropho-
resis (CE–MS) (Begou et al. 2017; Putri et al. 2013). In 
LC, the performance improvements in metabolic profiling 
delivered by ultra (high) performance liquid chromatog-
raphy (U(H)PLC) (Wilson et al. 2005), in terms of resolu-
tion, speed and sensitivity (a three- to fivefold increase), 
have resulted in analysis times in the range of 10–20 min 
per sample (Dunn et al. 2011; Lewis et al. 2016; Paglia 
et  al. 2012) compared to 40–60  min for conventional 
HPLC (Clayton et al. 1998). This increase in throughput is 
generally acceptable for small-scale animal studies, where 
sample numbers are typically in the 100–500 range. How-
ever, the numerical challenge provided by the need for 
higher throughput in drug discovery programs and larger 
studies (> 500) such as those associated biobanking/epi-
demiology etc., would clearly benefit from a more efficient 
solution with the ability to perform rapid and reproduc-
ible acquisitions to help address the analysis time burden 
associated with the metabolic profiling of large cohorts. 
Thus, current methods for the analysis of studies consist-
ing of 1000+ samples, can lead to an LC–MS instrument 
operating constantly for over 7 days (based on a 10-min 
LC methodology) in order to acquire the data in a single 
batch. This, in itself, can produce difficulties in logisti-
cal management for laboratories with limited staff and 
instrumentation. Additionally, lengthy analytical runs, or 
running large studies in multiple batches, can lead to a 
variation in ion response when looking at data across dif-
ferent days and increase the possibility of errors in data 
processing.
Reduced run time for this type of analysis (1–2 min 
per sample) has been achieved by eliminating the chro-
matography step and analysing the sample using DIMS 
(e.g. Chekmeneva et al. 2015). However, this approach 
can result in ion suppression, missing analytes and over 
estimation of metabolites due to isobaric interferences 
(Gray et al. 2016). An alternative approach to DIMS is to 
use a short (5 cm) UHPLC column with elevated mobile 
phase linear velocities and rapid gradients. This approach 
has been employed by the DMPK community for over 
15 years for the high throughput quantification of drugs 
and metabolites in serum and plasma (Plumb et al. 2001). 
More recently this approach has been demonstrated in 
metabolic profiling studies for the analysis of moderately 
polar metabolites using reversed-phase (RP) UHPLC–MS 
for both 2.1 (Plumb et al. 2005) and 1 mm id columns 
(Gray et al. 2016).
However, the biological matrices utilised in metabolomic 
studies encompass many different classes of compounds, 
which consequently exhibit a broad range of chemical prop-
erties. Complete coverage of all of these compounds using 
RP separations can be difficult especially for polar analytes 
that are poorly retained. These polar compounds e.g. carbo-
hydrates, organic acids and some biogenic amines, tend to 
elute in RPLC at the beginning of the gradient, often within 
the solvent front. This lack of retention results in inaccu-
rate identification/quantification of these polar compounds 
due to analyte co-elution and interference/ion suppression 
with background ions/unretained salts etc. The adoption of 
hydrophilic interaction liquid chromatography (HILIC) has 
enabled many polar compounds to be analysed (Chauve et al. 
2010) and, as a result, the dual analysis of samples such as 
urine using HILIC for the metabolic phenotyping of bio-
fluids has become commonplace (Creek et al. 2011; Spa-
gou et al. 2011) reviewed in e.g. (Spagou et al. 2010; Tang 
et al. 2016). Indeed the combination of RPLC and HILIC 
has begun to be used as standard practice where compre-
hensive profiles are required (Contrepois et al. 2015; Gika 
et al. 2008; Paris et al. 2016; Sun et al. 2017). Other modes 
of separation employed in the analysis of extremely polar 
compounds have proven to be reliable and reproducible, but 
in the case of e.g., normal phase and ion-exchange chro-
matography, compatibility issues with mass spectrometry 
and electrospray ionisation, due to the solvents and additives 
used, have made these techniques less attractive than HILIC 
for high throughput metabolomic studies.
In addition, advances in instrumentation have resulted in 
increasing interest in the application of ion mobility spec-
trometry (IMS) to metabolic phenotyping (Harry et al. 2008; 
Malkar et al. 2013; Rainville et al. 2017; Zhang et al. 2018) 
and lipidomics (Paglia et al. 2015a, b; Paglia and Astarita 
2017; Shah et al. 2013).
Here we demonstrate a similar approach to the reversed-
phase rapid microbore metabolic profiling (RAMMP) 
method described previously (Gray et  al. 2016) for the 
analysis of polar metabolites in urine using HILIC–MS, 
either alone or coupled to IMS-enabled MS data acquisi-
tion (HILIC–IMS–MS). The information obtained from IMS 
separation can also be used to generate collision cross sec-
tion (CCS) values representative of the interaction between 
Development of a rapid profiling method for the analysis of polar analytes in urine using HILIC–…
1 3
Page 3 of 11    17 
the surface area of the ion and the drift gas (Paglia et al. 
2015a). The resulting methodology was employed for the 
monitoring of the urinary metabolome resulting following 
the administration of the model human liver toxin tienilic 
acid (TA) to the rat.
2  Experimental
2.1  Chemicals and reagents
Water was obtained from an in-house Milli Q filtration 
system Millipore (Billercia MA, USA). LC–MS grade 
acetonitrile, methanol, isopropanol and formic acid were 
purchased from Sigma Aldrich (Gillingham, UK). Tienilic 
acid and its isomer were synthesised as described elsewhere 
(Rademacher et al. 2012). The LC–MS QC standard mix-
ture, containing sulfadimethoxine, sulfaguanidine and leu-
cine encephalin (used here as a system suitability test) was 
obtained from Waters Corporation (Milford MA, USA) and 
the major mix IMS/Tof calibration kit was obtained from 
Waters Corp (Wilmslow, UK).
2.2  Biological sample preparation for HILIC 
separation
Urine samples were obtained from male Sprague–Daw-
ley rats (supplied by Charles River Laboratories (Portage 
Ml), 250–300 g in weight) dosed intravenously with either 
250 mg/kg of TA or vehicle, as described in detail elsewhere 
(Coen et al. 2012). Urine samples were collected at three 
time points covering the periods 0–2, 2–6 and 6–24 h post 
dose. These urine samples were then diluted 1:9 v/v with 
LCMS grade water, then centrifuged at 13,000g to remove 
any particulates before 900 µL of acetonitrile was added to 
100 µL of the supernatant. A quality control (QC) sample 
was generated by pooling aliquots of each sample and ana-
lysed after every 10 samples throughout the course of the 
analytical batch (Gika et al. 2008). All the samples were 
thawed once prior to processing and QC generation. The 
individual study samples were injected in triplicate to make 
a total study batch containing 134 injections (not includ-
ing pre-analysis system conditioning injections). The study 
was performed at Michigan State University and subject to 
institutional ethical approval from an ethics committee and 
conducted subject to national guidelines for the conduct of 
animal studies.
2.3  Rapid HILIC–MS/MS and HILIC–IMS–MS/MS 
method
Chromatography was performed on a Waters ACQUITY 
I-Class chromatography system (Waters Corp, MA, USA), 
with the rapid microbore HILIC separation of the polar 
metabolites performed on a Waters BEH HILIC amide 
column (1.7 µm) with an internal column diameter of 
1.0 mm and an overall length of 5 cm. A gradient elu-
tion profile was employed using mobile phases consist-
ing of LC–MS grade deionised water and acetonitrile 
(Fisher Scientific, Loughborough UK) for phases A and 
B respectively, both containing 0.1% (v/v) formic acid. 
The flow rate was maintained throughout the separation 
at 0.2 mL/min with a column temperature of 50 °C and an 
injection volume of 0.2 µL. The separation was performed 
over 2.33 min with a starting composition of 99% mobile 
phase B. This composition was held at the acquisition start 
for 0.03 min before decreasing to 50% B over the next 
2.30 min. The mobile phase composition was returned to 
starting conditions (99% B) over 0.04 min, followed by a 
column re-equilibration phase of 0.96 min, giving a total 
acquisition cycle of 3.33 min. The liquid chromatography 
conditions were generated by scaling the gradient, sample 
injection volume (3.5 µL) and flow rate (0.4 mL/min) from 
a conventional HILIC separation developed by Paglia et al. 
(2012) which employed a 10 min gradient elution profile 
and a 2.1 × 150 mm column. Mobile phase composition 
and column stationary phase was maintained.
Mass spectrometry data were acquired using a Waters 
Synapt G2-Si (Waters Corp, Wilmslow, UK) set to col-
lect the data in continuum format using electrospray ioni-
sation (ESI) in positive ionisation mode, over the mass 
range of m/z 50–1200. Capillary, sampling cone, and 
extraction cone voltages were set to 1.5 kV, 30 V and 5 V 
respectively, with the source temperature set to 120 °C 
and desolvation temperature 500 °C. Gas flow rates were 
set at 800 L/h for the desolvation gas and 50 L/h for the 
cone gas, and the mass spectrometer was set to acquire in 
sensitivity mode with a scan time of 0.1 s. Fragment ion 
information was acquired using collision induced dissocia-
tion and a collision energy ramp from 20 to 40 V. In order 
to decrease broadening of the chromatographic peaks, the 
internal diameter of the tubing connecting the column to 
the electrospray probe was reduced to 0.0025 inches and 
a reduced flow (50 µL) capillary probe was used. Real 
time lockmass correction was achieved by infusing leucine 
enkephalin at 10 µL/min through a lockspray probe and 
acquired every 30 s.
Additionally, each sample was also analysed with the 
ion mobility function of the Synapt G2-Si enabled. The 
ion mobility T-wave velocity was set to 650 m/s, with a 
pulse height of 40 V and nitrogen was used as the drift 
gas, set to a flow rate of 180 mL/min. Calibration of the 
ion mobility function for determining compound collision 
cross section was achieved using the Waters major mix 
IMS/Tof calibration kit.
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2.4  Data processing
All multivariate raw data were processed using Progenesis 
QI (Nonlinear dynamics, Newcastle UK) which performed 
run alignment, peak picking, adduct deconvolution and 
eventual feature (linked mass/retention time pairs) database 
searching. Principle component analysis (PCA), using Pareto 
scaling, was performed using Ezinfo (Umetrics, Umeå SE) 
in order to visualise group separation, and orthogonal partial 
least squared discriminate analysis (OPLS-DA) to identify 
significant features. In the assessment of chromatographic 
performance, specific target compounds were extracted and 
integrated using TargetLynx (Waters Corporation, Milford 
USA). The databases used to generate potential identifica-
tions were the Metlin MS/MS (Scripps Institute, CA, USA) 
and the human metabolome database (HMDB) (Wishart 
et al. 2018) with precursor and fragmentation ion accuracy 
set to 10 ppm. For CCS measurements, the IROA CCS data-
base (Waters Corporation, Milford USA) with a tolerance to 
the database value of 2.5% was used.
3  Results and discussion
3.1  Chromatographic method development
The aim of the present study was to develop a rapid HILIC-
based separation for the analysis of polar compounds to 
complement the rapid RP-microbore method previously 
described by Gray et al. (2016) which demonstrated the 
utility of a rapid method for the metabolic profiling of sam-
ples such as urine. For this a HILIC method used for the 
analysis of polar biological compounds on a conventional 
2.1 × 150 mm analytical column (Paglia et al. 2012) was 
adapted for a 1.0 × 50 mm microbore column. The acquisi-
tion time, gradient and profile were geometrically scaled in 
order to maintain the same separation and retention charac-
teristics using the smaller column compared to the original 
separation. The mobile phase linear velocity was increased 
providing more column volumes of solvent to define the 
gradient, leading to improved peak capacity in addition 
to maintaining the appropriate column volumes of mobile 
phase required for re-equilibration. This is an important con-
sideration with HILIC-based methods as the long column 
re-equilibration times often needed in this LC mode can 
significantly extend the time required for sample analysis. 
In addition, reproducibility between samples can be greatly 
affected if a sufficient number of column volumes of mobile 
phase have not been used in the gradient re-equilibration 
phase.
The data displayed in Fig. 1 demonstrates the scal-
ing of the previous HILIC based separation (Paglia et al. 
2012) from a 12-min method on a conventional 2.1 mm 
column to 3.3  min, on a 1  mm id column, using the 
Rapid HILIC method (using three probe analytes present 
in the LC–MS QC sample mixture (1) sulfadimethoxine 
(m/z = 311.08), (2) sulfaguanidine (m/z = 215.06), (3) 
leucine enkephalin (m/z = 556.28). As can be seen from 
the resulting mass chromatograms, the relative reten-
tion of the three compounds has been conserved in the 
Rapid method (see also supplementary Table S1) pro-
viding an average peak width of approximately 3.5 s at 
the base. This Rapid HILIC method delivered narrower 
peaks than the conventional HILIC method, as would be 
expected from chromatographic theory, where peak width 
is directly proportional to column length, thus halving 
the column length should deliver narrower peaks. After 
confirming that the rapid method had been successfully 
scaled down by analysing the LC–MS QC mixture, the 
Rapid HILIC method was then applied in the analysis 
of biological samples ultimately enabling the analysis of 
the 134 samples in the sample set in ca. 7 h (compared 
Fig. 1  Overlaid XIC chromato-
grams from (a) the conventional 
10 min HILIC analysis and 
(b) the 3.33 min. Rapid analysis 
of three system suitability 
standards (1) sulfadimethoxine 
(m/z = 311.08) (2) sulfaguani-
dine (m/z = 215.06) (3) leucine 
enkephalin (m/z = 556.28) dem-
onstrating the conservation of 
the HILIC retention mechanism
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to ca. 1 day for the conventional method). Despite the 
reduction in run time with this Rapid HILIC method, 
adequate retention of polar metabolites in rat urine was 
still achieved, as demonstrated in Figure S1, which shows 
extracted ion chromatograms of endogenous compounds 
tentatively identified as a hexose sugar (most probably 
glucose), 1- or 3-methylhistidine, kynurenic acid and 
creatinine.
In order to rapidly assess the robustness of the chroma-
tographic separation within an analytical batch, a selec-
tion of endogenous compounds (Table 1) known to be 
present in urine that possessed different chromatographic 
properties and eluted across the gradient, were used to 
monitor changes in retention time, integrated peak area 
and peak asymmetry. Each compound was integrated 
from all of the pooled quality control samples used to 
monitor the analysis of the batch of 134 sample injec-
tions. The coefficient of variance (% CV) of retention 
time, peak area and asymmetry was calculated for each 
of these compounds, as shown in Table 1. The system 
showed excellent reproducibility, with coefficients of 
variation for peak retention between e.g., 0.31% (trypto-
phan) and 6.3% (hexose sugar). The LC peak symmetry 
varied between 0.71 and 3.24, which highlights the range 
of chromatographic peak shapes associated with this 
mode of LC, and serves to illustrate the complexity of the 
HILIC based separation mechanism. Thus peak shape in 
HILIC is influenced by pH, buffer concentration, solvent 
composition, temperature and the ion-exchange capability 
of the stationary phase, making it difficult to optimize the 
methodology for all the different types of analyte present 
in complex biological matrices. These limited data, how-
ever, indicate that despite the rapid gradient and short 
re-equilibration time, the system produced excellent run-
to-run reproducibility (e.g. see Figure S2).
3.2  Biological samples
The Rapid HILIC/MS methodology was applied to the 
analysis of rat urine samples following the intravenous 
administration of either dose vehicle or tienilic acid 
as described elsewhere (Coen et al. 2012). The system 
showed excellent tolerance to the analysis of rat urine 
(which was diluted 1:9 with acetonitrile), as demon-
strated by the stability of the retention time, peak area 
and peak asymmetry data provided in Table 1 for a selec-
tion of the detected features. Analysis of the resulting 
data using multivariate analysis (PCA) revealed a total 
of 3007 LC–MS features in the samples, with an average 
peak width of 6.6 s at the base, resulting in a peak capac-
ity of 28 for the 3-min separation. Based on bioanalytical 
guidance provided by the FDA (FDA 2001) a % CV of 
< 15–20% has been widely regarded as the standard for 
acceptance of data for drug bioanalysis using targeted 
LC–MS assays. However, for biomarkers the FDA Guid-
ance acceptance criteria are somewhat less strict, and 
pragmatically have generally been increased for metabolic 
phenotyping to allow a % CV of 20–30% for untargeted 
metabolomic profiling methods (Brunius et  al. 2016; 
Dunn et al. 2012). It should be noted that, as we have 
reported elsewhere, the CV of detected peaks is response 
dependent (e.g. see Gika et al. 2008) with less intense 
peaks showing lower repeatability (see Figure S3a). 
Using these criteria some 750 of the features detected by 
HILIC–MS in the QC samples had CVs of less than 30%, 
with 575 having CVs of less than 20% and 429 with CVs 
of less than 15% (77 and 57% of these totals respectively). 
These data are provided in Table S2. Whilst the num-
ber of detected features is undoubtedly lower than that 
obtained with conventional HILIC LC–MS analysis this 
is entirely to be expected [see e.g., the previously reported 
Table 1  Values of chromatographic performance: retention time deviation, integrated peak area* variability and peak asymmetry values for 
selected endogenous compounds present in rat urine obtained from pooled QC injections (n = 17) across the rapid HILIC–MS analytical batch
See also Table S2 for further information on integrated peak area* variability on all the features showing a CV of less than 30% in the data 
obtained for the 17 QC samples analysed in this study
Possible ID m/z Retention time Area Peak asymmetry
[M+H]+ Mean (n = 10) Std dev %CV Mean (n = 10) Std dev %CV Mean (n = 10) Std dev %CV
Kynurenic acid 190.04 1.22 0.01 0.53 4896.49 1000.24 20.43 3.24 0.16 4.89
Alanine 90.03 1.53 0.01 0.60 7.94 1.72 21.65 0.99 0.29 29.35
Tryptophan 205.07 1.26 0.00 0.31 519.64 128.62 24.75 1.63 0.22 13.38
Hexose sugar 181.07 0.29 0.02 6.23 140.01 29.95 21.39 1.47 0.22 14.87
Threonine 120.06 1.49 0.01 0.43 15.09 3.83 25.40 1.43 0.33 22.91
Creatinine 114.07 1.39 0.00 0.33 4747.41 241.92 5.10 0.71 0.10 14.54
Indole 118.06 0.34 0.01 2.49 561.51 90.98 16.20 1.34 0.23 17.40
Leucine 132.10 1.48 0.00 0.33 404.50 72.16 17.84 2.09 0.49 23.27
1- or 3 -methylhistidine 170.06 0.53 0.02 2.90 447.30 117.79 26.33 1.49 0.33 22.29
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results for the RAMMP reversed-phase RP method com-
pared to a conventional separation (Gray et al. 2016)]. 
However, the PCA data showed a clear separation of the 
tienilic acid samples from those of the controls. The drug 
metabolite profile in these samples has been previously 
investigated (Coen et  al. 2012; King et  al. 2018) and 
examination of the HILIC–MS data for the presence of 
either drug or drug-related signals [easily identifiable due 
to the characteristic chlorine isotope pattern provided by 
the presence of 2 chlorine atoms present as substituents 
on the drug (King et al. 2018)] showed that they were 
sufficiently hydrophobic to have eluted close to, or in, the 
solvent front and therefore did not contribute to the PCA 
separation. The results from OPLS-DA of these data are 
shown in Figure S4 demonstrating the group separation 
between TA- and vehicle-dosed animals with intergroup 
separation across the y-axis for the TA-dosed animals. 
This corresponds, to some extent, to the sample collec-
tion time point with the TA-dosed animals following a 
time (and animal) dependent metabolic trajectory over 
the 24 h time course of the study. The inter-animal dif-
ferences highlighted indicates a, not unexpected, degree 
of variability in the response of these animals to drug 
treatment. However, by 24 h post dose all of the animals 
appeared to occupy a similar “metabolic” space. The 
related S-plot is shown in Figure S5 highlighting those 
features of greatest significance to the group discrimina-
tion between the groups.
Critical to successful metabolic profiling is the acqui-
sition of searchable precursor and product ion MS data, 
enabling drug, drug metabolite and endogenous com-
pound identification by either database searching or 
classical de novo data interpretation. Modern database 
searching tools employ a scoring algorithm to grade qual-
ity of the data match (Benton et al. 2008). Therefore, 
any metabolic profiling analytical system should provide 
acceptable MS (MS/MS) data quality, which in turn relies 
on the capability of the LC system to minimise analyte 
co-elution. A selection of endogenous ions were used to 
assess the analytical performance of the HILIC separa-
tion (Table 1) in addition to undergoing database searches 
using Metlin MS/MS (Scripps Institute, CA, USA) and 
the  HMDB, in order to generate potential compound 
identifications.
The extracted MS/MS spectrum for m/z 190.04 ion, 
with the database ID of kynurenic, acid is displayed in 
Fig. 2a, and shows excellent spectral quality data which 
was easily interpretable and resulted in an experimental 
to theoretical fragment ion score of 88.7 (Fig. 2b). Simi-
lar good-quality high collision energy spectral data were 
obtained for compounds provisionally identified as a hex-
ose sugar e.g. glucose (Figure S6) and either 1- or 3-meth-
ylhistidine (Figure S7).
3.3  Ion mobility spectrometry (IMS) enabled HILIC–
MS (HILIC–IMS–MS)
As previously described, the shorter column length and anal-
ysis time employed in the RAMMP methodology inevitably 
results in reduction in the number of features detected in the 
sample when compared to standard 10 to 20 min analyti-
cal methodologies (Gray et al. 2016). Some signal loss can 
be attributed to ion suppression in the source as a result of 
analyte co-elution and matrix effects. However, some of the 
reduction in detected features may also be due to co-elution 
of compounds, including isobars, and the “masking” of sig-
nals from low signal intensity metabolites by more intense 
signals from co-eluting compounds.
The millisecond time scale of IMS separations is con-
veniently in-between those of chromatography (seconds) 
and TOF–MS, where spectral data is acquired in micro-
second packets. This allows IMS enabled MS to facilitate 
an extra dimension of resolution to the analytical process 
as well as providing “cleaner” mass spectra for individ-
ual analytes by reducing the number of co-eluting inter-
ferences. Previously we have shown that, for the same 
reversed-phase LC conditions, UHPLC–IMS–MS deliv-
ered approximately 30–50% more detected features than 
UHPLC–MS alone (Rainville et al. 2017). As we have 
previously noted, this cannot be because of a reduction in 
matrix effects as this separation occurs post ESI, but must 
rather be due to the “unmasking” of spectra from minor 
components previously hidden by the dominant component 
eluting from the column at that particular retention time 
(Rainville et al. 2017). To evaluate the impact of IMS on 
the Rapid HILIC separation the rat urine samples were 
reanalysed on the same LC–MS platform with IMS ena-
bled. The resulting Rapid HILIC IMS–MS/MS analysis of 
the urine QC samples, which resulted in the detection of 
some 6711 features, is illustrated in Fig. 3, which shows a 
3-D plot where the IMS drift time is plotted against reten-
tion time and analyte response. This graphically illustrates 
that numerous ions that co-eluted under the LC/MS condi-
tions used were resolved by IMS, and thus are uniquely 
detected by the combination of LC–IMS–MS/MS. A fur-
ther illustration of this enhanced separation is shown by 
employing a 2D ion map (Figure S8) where the complexity 
of the data can be clearly observed.
Using the criteria of a CV of 30% or less a total of 950 
features present in the QC samples were acceptable for 
HILIC–IMS–MS, with 526 having CVs of less than 20% 
and 211with a CV of less than 15% (55 and 22% of the 
total respectively). These data are provided in Table S3. 
This increased variability in response seen with the IMS 
data, compared to the conventional MS results, could be 
attributed to the introduction of variability in ion transmis-
sion through the ion mobility cell or, as discussed earlier, 
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to the natural increase in variability resulting from an 
increase in the number of low intensity minor features 
detected (Gika et al. 2008) (see Figure S3b). The resulting 
PCA and OPLS-DA of the data derived from this analysis 
again showed good separation of the test and control ani-
mals (see Figure S9). Once again the spread in the data 
for the TA-dosed animals reflects time-related changes in 
response to drug administration similar to those seen with 
HILIC–MS.
A careful inspection of these data revealed that the 
average observed peak width seen with the combined 
LC–IMS–MS separation was 3.8 s compared to 6.6 s for 
LC–MS alone (Fig.  4), giving an increase in LC peak 
capacity from 28 to 51. The added capacity to separate 
analytes and increase system peak capacity should provide 
improved mass spectral data thus giving higher confidence 
in metabolite identification and resulting in fewer false posi-
tives. The reduction in observed LC peak width for the IMS-
enable analysis can probably be attributed to the resolution 
of co-eluting isobaric metabolites. It is also noteworthy that, 
even though IMS–TOF–MS is widely reported to be less 
sensitive than standard TOF–MS, the multivariate statistical 
analysis of the IMS-enabled data set resulted in an increase 
in detected features from the 3007 by LC–MS to 6711 using 
LC–IMS–MS.
Fig. 2  a High collision energy mass spectrum of m/z 190.0550 m/z at a retention time of 1.21 min, with fragment ions, b Progenesis QI output 
of corresponding feature (nominal mass of 189.0434 Da) at a retention time of 1.21 min with HMDB database search result of kynurenic acid
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The IMS and non-IMS data from the QC samples were 
subjected to PCA with the result displayed in Fig. 5. Here 
we can see that the two data groups are clearly separated 
with, in addition, apparent improved analytical robust-
ness indicated by the tighter clustering of the IMS QC 
samples when compared to non-IMS QCs. The features 
detected in the metabolic profiling analysis were sub-
jected to a database search based on precursor ion m/z 
and fragment ion information. The potential identity of 
these molecules was then further supported by compar-
ing the experimentally derived ion mobility CCS data 
with that of the Waters IROA CCS database, built using 
CCS values generated from authentic compound stand-
ards. As an example, the data shown in Figure S10 illus-
trates the database search for 4-hydroxy-2-quinolinecar-
boxlic acid (kynurenic acid), where the experimentally 
determined CCS result is within 0.32 of the database 
value, with additional CCS values presented in Table 2. 
These experimentally determined CCS measurements are 
within 5% of the CCS values from the experimentally 
derived CCS database and those of the theoretical CCS 
values (Zhou et al. 2016). The added capacity to separate 
metabolites, and thereby increase peak capacity, provides 
higher confidence in metabolite identification and should 
result in fewer false positives.
Based on the levels of compound identification criteria 
described by the Metabolomic Standards Initiative (MSI) 
(Sumner et al. 2007), kynurenic acid, tryptophan, creati-
nine, indole and leucine have been identified to level 2, with 
MS/MS and CCS database matches. The availability of two 
orthogonal sets of data, based on physicochemical proper-
ties, for comparison against both reference MS/MS and CCS 
libraries, as well as one built internally from experimental 
data, has increased the confidence in the resulting potential 
identifications. In order to achieve an identification at level 
1, complementary data generated from an authentic stand-
ard is required, especially if the compound of interest is a 
potential biomarker candidate.
It is clear from the increasing number of applications of 
LC–IMS in metabolic phenotyping (Harry et al. 2008; Mair-
inger et al. 2018; Malkar et al. 2013; Rainville et al. 2017) 
and lipidomics (Hinz et al. 2018; Paglia et al. 2015a; Shah 
et al. 2013) that the combination of LC, IMS and MS has 
much to offer for both analyte separation and identification, 
and this can be expected to be an area of keen interest for 
the future.
4  Conclusion
HILIC based microbore UPLC–MS performed using short 
columns, with rapid gradients and elevated mobile phase 
linear velocities, provides a suitable analytical platform with 
which to perform high-throughput endogenous metabolic 
profiling of polar metabolites in urine. Compared to a con-
ventional UPLC–HILIC/MS method, the developed Rapid 
HILIC method provided a fourfold reduction in analysis 
time, a 75% reduction in solvent use, and an 18-fold reduc-
tion in sample consumption over a conventional HILIC 
UPLC method, whilst maintaining the ability to detect criti-
cal discriminating features between different sample groups. 
Combining both Rapid HILIC- and RP-RAMMP methods 
would provide an efficient and rapid means of screening 
large numbers of samples, especially when coupled with 
IMS mobility and MS to increase feature detection and 
improve metabolite identification.
Fig. 3  A 3D plot of a pooled rat urine QC showing chromatographic 
retention time, IMS drift time separation and ion intensity. Co-eluting 
ions have been separated by the IMS with some at a lower intensity 
otherwise hidden by more intense species
Fig. 4  Distribution of feature peak width from the Rapid HILIC 
acquisition with and without IMS
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Table 2  Measured CCS 
values for endogenous target 
compounds (§) in addition to 
the predicted CCS measurement 
(*) generated from the MetCCS 
predictor (http://www.metab 
olomi cs-shang hai.org/MetCC 
S/) (Zhou et al. 2016), with 
the difference in CCS result of 
the measured values compared 
to experimentally derived 
metabolic profiling CCS library 
(ǂ) and the predicted CCS value
Possible ID m/z CCS










Kynurenic acid 190.04 134.9 0.32 139.7 − 4.8
Alanine 90.03 – – 117.4
Tryptophan 205.07 143.3 − 1.74 144.7 − 1.4
Hexose sugar (glucose) 181.07 133.4 – 136.7 − 3.3
Threonine 120.06 – – 122.0
Creatinine 114.07 120.4 − 1.03 119.6 0.8
Indole 118.06 122.1 − 0.25 124.7 − 2.6
Leucine 132.10 124.9 − 3.14 130.2 − 5.3
1- or 3- methylhistidine 170.06 132.1 – 138.8 -5.7
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